Big Buttons

• PFMs can get 2.5% credit card processing

  A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%. read more →

• Phoenix compounders, rise!

  The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5. read more →

• APC election results: directors and bylaws

  See the results of APC's elections, including four new directors and several changes to our bylaws. read more →

• Bring us your expertise — join an APC standing committee

  We’re seeking knowledgeable members for seven 2025 APC standing committees. Is that you? read more →

• You don’t have to miss our GLP-1 briefing

  Our briefing, “What's Up with GLP-1 Compounding (And What's Next)?” is now available on demand. read more →

• PCAC votes against four nominated bulk drug substances

  FDA’s Pharmacy Compounding Advisory Committee voted at a meeting Tuesday against adding four substances to the 503A bulks list. read more →

• Did someone mention glass houses?

  Oopsie! The FDA has cited Novo Nordisk for “quality lapses” at one of the company’s two Ozempic manufacturing plants. read more →

• GLP-1s: Keep your patients informed

  The P3 October newsletter is perfect for explaining GLP-1s to your patients. read more →

More News

FDA’s Pharmacy Compounding Advisory Committee voted at a meeting Tuesday against adding four substances to the 503A bulks list of substances that can be used for compounding: L-theanine, ibutamoren mesylate, ipamorelin, and kisspeptin-10. The committee also voted unanimously to add hydroxyprogesterone caproate to the FDA list of withdrawn drugs that should not be compounded. The next PCAC meeting is scheduled for Dec. 4.